GHRS

GH Research PLC

GHRS, USA

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

https://www.ghres.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GHRS
stock
GHRS

We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business Growth simplywall.st

Read more →
GHRS
stock
GHRS

Stempoint Capital LP Acquires New Stake in GH Research PLC $GHRS MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$30.375

Analyst Picks

Strong Buy

5

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.77

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-4.81 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.64 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.04

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 68.33% of the total shares of GH Research PLC

1.

Bvf Inc

(14.2315%)

since

2025/06/30

2.

RA Capital Management, LLC

(12.3759%)

since

2025/06/30

3.

RTW INVESTMENTS, LLC

(8.932%)

since

2025/06/30

4.

FMR Inc

(8.2092%)

since

2025/06/30

5.

Fidelity Growth Compy Commingled Pl S

(4.1138%)

since

2025/07/31

6.

Cormorant Asset Management, LLC

(3.2396%)

since

2025/06/30

7.

Deep Track Capital, LP

(3.2243%)

since

2025/06/30

8.

The Toronto-Dominion Bank

(3.1715%)

since

2025/06/30

9.

Fidelity Growth Company Fund

(2.5246%)

since

2025/07/31

10.

Jefferies Financial Group Inc

(1.1435%)

since

2025/06/30

11.

Verition Fund Managegment, LLC

(1.0598%)

since

2025/06/30

12.

5AM Venture Management, LLC

(0.9232%)

since

2025/06/30

13.

Fidelity Growth Company K6

(0.901%)

since

2025/07/31

14.

UBS Group AG

(0.7393%)

since

2025/06/30

15.

Fidelity Series Growth Company

(0.6787%)

since

2025/07/31

16.

Fidelity Select Biotechnology

(0.5478%)

since

2025/07/31

17.

Morgan Stanley - Brokerage Accounts

(0.453%)

since

2025/06/30

18.

Alyeska Investment Group, L.P.

(0.4111%)

since

2025/06/30

19.

Millennium Management LLC

(0.3283%)

since

2025/06/30

20.

StemPoint Capital LP

(0.1625%)

since

2025/06/30

21.

Morgan Stanley Inst Inception I

(0.1202%)

since

2025/06/30

22.

Morgan Stanley Inception

(0.1202%)

since

2025/06/30

23.

BlackRock Inc

(0.1044%)

since

2025/06/30

24.

AdvisorShares Psychedelics ETF

(0.0879%)

since

2025/08/29

25.

HighVista Strategies LLC

(0.0842%)

since

2025/06/30

26.

EQ/Morgan Stanley Small Cap Growth K

(0.0787%)

since

2025/07/31

27.

Northern Trust Corp

(0.0628%)

since

2025/06/30

28.

AdvisorShares Investments, LLC

(0.0617%)

since

2025/06/30

29.

iShares MSCI Ireland ETF

(0.059%)

since

2025/08/31

30.

Fidelity Nasdaq Composite Index

(0.0575%)

since

2025/07/31

31.

Geode Capital Management, LLC

(0.0558%)

since

2025/06/30

32.

A4Investments SICAV SIF ACCI IlanaA2EURH

(0.0161%)

since

2025/08/31

33.

Virtus LifeSci Biotech Clinical Trls ETF

(0.0154%)

since

2025/08/29

35.

Northern Small Cap Core I

(0.0113%)

since

2025/06/30

36.

NT Quality SCC US Fund - L

(0.0057%)

since

2025/06/30

37.

NT Quality Small Cap Core

(0.0057%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2713

Latest Release

Date

2025-09-30

EPS Actual

-0.23

EPS Estimate

-0.235

EPS Difference

0.005

Surprise Percent

2.1277%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(3)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.